An ongoing dialogue on HIV/AIDS, infectious diseases,
May 27th, 2010
HIV Treatment is Prevention!
The Lancet has just published a large prospective study demonstrating the protective effect of HIV treatment on the risk of viral transmission:
3381 couples were eligible for analysis … Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0·37 (95% CI 0·09—2·04) per 100 person-years in those who had initiated treatment and 2·24 (1·84—2·72) per 100 person-years in those who had not—a 92% reduction (adjusted incidence rate ratio 0·08, 95% CI 0·00—0·57, p=0·004).
A similar observation was made in an earlier study presented at CROI 2009, not yet published. Astoundingly, the rate of transmission in this Lancet paper could have been be zero if analyses were limited only to those with undetectable viral loads on treatment.
So here’s the bottom line: HIV treatment dramatically, hugely, ginormously reduces the risk of HIV transmission.
(My daughter several years ago predicted that ginormous would become a word. She was right.)
Yes, we can quibble with some of the details — the 2009 study did not include viral load measurements, this one in the Lancet was actually part of a study of HSV treatment hence the results are observational, protection from infection is not 100% — but is there any doubt that HIV treatment is currently our most effective way of preventing the spread of HIV?
Some will say that the definitive study on this issue is HPTN 052, which randomizes the HIV-infected member of a serodiscordant couple to go on treatment or to wait until the CD4 cell count drops below 250. The primary endpoint is the rate of infection among the seronegative partners.
But that study is likely to exclude those most likely to transmit HIV, since it’s limited to people with HIV who have no symptoms, a relatively high CD4 cell count, and hence on average a lower viral burden.
At this point, it seems a no-brainer to me. Treatment is prevention.
Categories: HIV, Infectious Diseases, Patient Care, Research
Tags: antiretroviral therapy, CROI, HIV, HPTN 052, Lancet, prevention
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “HIV Treatment is Prevention!”
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
-
From the Blog — Most Recent Articles
- ID Things to Be Grateful for — 2025 Edition November 24, 2025
- When AI Gets the Medical Advice Wrong — and Right November 18, 2025
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin November 13, 2025
- Favorite ID Fellow Consults: Johns Hopkins Edition November 7, 2025
- Two Covid Vaccine Studies — One Actionable, the Other Not So Much October 28, 2025
FROM NEJM — Recent Infectious Disease Articles- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025Highly pathogenic avian influenza A(H5N1) virus has spread among dairy cattle, with virus detected in milk samples. In this report, virus viability after cold storage or pasteurization is assessed.
- Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 December 4, 2025Results from recently published, peer-reviewed studies support the safety and effectiveness of immunizations against Covid-19, RSV, and influenza.
- Glucocorticoids for Pneumonia in Africa — Old Therapy, New Context December 4, 2025The African continent is home to 1.55 billion people, one fifth of the world’s population, spread over an area larger than the United States, China, and India combined. The disease burden is enormous,1 and health care resources are severely constrained. In one multinational survey, one in eight hospitalized...
- The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation December 4, 2025The U.S. administration recently unveiled its new approach to global health. A retreat from multilateralism, a geopolitical emphasis, and rushed transitions could threaten progress.
- Empyema Necessitans December 4, 2025A 66-year-old man presented with 2 weeks of shortness of breath and cough, 5 days of left flank pain, and 2 days of a rapidly expanding mass on his left side.
- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster


This is revolutionary discovery that can extinguish the epidemic if we can provide cheap, instant rapid accurate self-administered ID of new HIV infection along with 24/7 cheap access to first line therapy.
Yep. Big ifs there, I acknowledge.
But something like this seems to be happening within certain communities — MSM in San Francisco and injection drug users in Vancouver. With a higher proportion on treatment, there’s a suggestion that incidence is declining.
In our clinic here in Nigeria, we have experienced 100% success rates in prevention of transmission in serodiscordant couples who want to get pregnant without access to high tech methods. We just advocate the couple to wait till infected partner has an undetectable viral load and they have unprotected sex or with the condom slit at the tip during the woman’s fertile period. If only we can assure cheap, properly monitored undisrupted treatment…
I appreciate your highlighting this important study. It is my sense that people who successfully access and sustain treatment with ART are different in many ways. I advocate for universal access to care and ART is part of that, but I wonder if the results will be sustained with all persons–I hope so, but I wonder.